Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer

NCT ID: NCT01839773

Last Updated: 2024-07-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 238 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-03-31
• Study Completion Date: 2015-08-31

Brief Summary

The objective of this study is to evaluate the efficacy and safety of DHP107 (Oral paclitaxel) in comparison to Taxol®(IV paclitaxel) in Patients With Metastatic or Recurrent Gastric Cancer After Failure of 1st Line Chemotherapy With Fluoropyrimidine +/- Platinum.

Conditions

Stage IV Gastric Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

DHP107 (oral paclitaxel)

DHP107 (oral paclitaxel) will be administered weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.

Group Type: EXPERIMENTAL

Paclitaxel

Intervention Type: DRUG

Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent

Taxol® (IV paclitaxel)

Taxol® (IV paclitaxel) will be administered 3-weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.

Group Type: ACTIVE_COMPARATOR

Paclitaxel

Intervention Type: DRUG

Premedication, IV infusion on day 1 of 3-week cycle until progression, unacceptable toxicity or withdrawal of informed concent

Interventions

Paclitaxel

Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent

Intervention Type: DRUG

Paclitaxel

Premedication, IV infusion on day 1 of 3-week cycle until progression, unacceptable toxicity or withdrawal of informed concent

Intervention Type: DRUG

Other Intervention Names

DHP107; Taxol®

Eligibility Criteria

Inclusion Criteria

1. ≥20 years of age

2. Histologically or cytologically confirmed unresectable, recurrent or metastatic gastric cancer

3. Failure of a first line therapy with fluoropyrimidine +/- platinum for metastatic or recurrent disease.(Adjuvant chemotherapy is not considered as a first line chemotherapy unless recurrence developed within 6 months of completion of adjuvant therapy.)

4. Adequate bone marrow, liver and renal functions

5. INR ≤ 2.0

6. ECOG performance status ≤ 2

7. Neuropathy grade ≤ 1

8. Life expectancy of at least 3 months

9. Measurable lesion according to RECIST version 1.1 on CT scan

10. Written informed consent

11. Patients of child bearing age have to agree to the usage of adequate contraception from before the registration to the study, during the participation period and 90 days after the end of treatment. Female of child bearing age has to show negative for urin pregnancy test within 7 days from beginning of the start of administration. Amenorrhea status has to be sustained for at least 12 months to be considered non-pregnant in case of postmenstrual women.

Exclusion Criteria

1. Major infectious disease, neurological disorder, or bowel obstruction.

2. Patients with CNS metastases(confirmed through brain imaging if there are symptoms)

3. Patient diagnosed with another cancer type (except non-melanoma skin cancer, cervical cancer, or any other cancer that did not recur or metastasized for more than 5 years and considered as complete remission can be registered)

4. Patient who received radiation therapy within past 2 weeks or who had major surgery including organ resection within past 4 weeks from random assignment date

5. Patient with the history of failure to the taxane chemotherapy

6. Patient who need chronic concomitant use of P glycoprotein, immune suppressor, proton pump inhibitor, or H2-receptor antagonist during the period of clinical trial

7. Chronic treatment using steroid (except oral, local injection, or for externally applied) or other immune suppressor

8. Patient with myocardial infarction, congestive heart failure, arrhythmia showing abrupt change in the ECG, severe or unstable angina, or other serious heart disease

9. Patient with other serious internal disease (chronic obstructive or chronic inhibitory lung disease including shortness of breathe at rest due to all reasons, uncontrollable diabetes and hypertension)

10. History of abuse of a drug or alcohol within 3 months

11. Lactating or pregnant women, or patient (or spouse) who has no intension of using, or cannot use very effective mean of contraception

12. Patient who has or is suspected to have problem in bile acid secretion

13. Patient with active gastrointestinal bleeding, or taking oral anti- vitamine K (With the exception of low dose of Warfarin and acetylsalicylic acide when INR≤2.0)

14. History of serious hypersensitive reaction to the main ingredient or the excipient of the investigational drug

15. History of being seropositive for HIV (HIV test is not a prerequisite).

16. Patients with gastrointestinal dysfunction or on enteral feeding

17. Other patients who are deemed inadequate to participate in the clinical trial by the investigator

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Daehwa Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Inje University Haeundae Paik Hospital

Busan, , South Korea

Kyungpook National University Medical Center

Daegu, , South Korea

National Cancer Center

Goyang-si, , South Korea

Chonnam National University Hwasun Hospital

Jungnam, , South Korea

Seoul National University Bundang Hospital

Seongnam-si, , South Korea

Yonsei University Severance Hospital

Seoul, , South Korea

Samsung Medical Center

Seoul, , South Korea

Yonsei University Gangnam Severance Hospital

Seoul, , South Korea

Seoul St. Mary's Hospital

Seoul, , South Korea

Asan Medical Center, University of Ulsan College of Medicine

Seoul, , South Korea

Asan Medical Center

Seoul, , South Korea

Korea University Guro Hospital

Seoul, , South Korea

Ajou University Hospital

Suwon, , South Korea

Countries

South Korea

References

Kang YK, Ryu MH, Park SH, Kim JG, Kim JW, Cho SH, Park YI, Park SR, Rha SY, Kang MJ, Cho JY, Kang SY, Roh SY, Ryoo BY, Nam BH, Jo YW, Yoon KE, Oh SC. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Ann Oncol. 2018 May 1;29(5):1220-1226. doi: 10.1093/annonc/mdy055.

Reference Type: DERIVED

PMID: 29438463 (View on PubMed)

Other Identifiers

107CS-3

Identifier Type: -

Identifier Source: org_study_id